Immunosuppressive drugs, immunophilins, and functional expression of NCX isoforms

Advances in Experimental Medicine and Biology

Volumn 961, Issue , 2013, Pages 275-287

  Rahamimoff, Hannah ^a   Elbaz, Benayahu ^a   Valitsky, Michael ^a   Khatib, Mahdi ^a   Eskin Schwartz, Marina ^a   Elmaz, Daniela ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cyclophilin A; Cyclophilin B; Cyclosporin A; FK506 (Tacrolimus); Immunosuppressive drugs; PSC833 (Valspodar); Rapamycin (Sirolimus)

Indexed keywords

CYCLOPHILIN A; CYCLOPHILIN B; CYCLOSPORIN A; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CALCIUM EXCHANGE PROTEIN 1; SODIUM CALCIUM EXCHANGE PROTEIN 2; SODIUM CALCIUM EXCHANGE PROTEIN 3; TACROLIMUS; UNCLASSIFIED DRUG; VALSPODAR;

AORTA MEDIA; BLOOD BRAIN BARRIER; CELL STRAIN HEK293; CONFERENCE PAPER; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; GENETIC TRANSFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TRANSPORT; SMOOTH MUSCLE FIBER;

EID: 84873583146     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-4756-6_23     Document Type: Conference Paper

References (76)

1. S.S. Ahmed, H.W. Strobel, K.L. Napoli, J. Grevel, Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. J. Pharmacol. Exp. Ther. 265, 1047-1054 (1993)
2. S.S. Ahmed, K.L. Napoli, H.W. Strobel, Oxygen radical formation due to the effect of varying hydrogen ion concentrations on cytochrome P450-catalyzed cyclosporine metabolism in rat and human liver microsomes. Adv. Exp. Med. Biol. 387, 135-139 (1996)
3. 2+ exchanger: from molecular biology to therapeutic perspectives. Pharmacol. Rev. 56, 633-654 (2004)
4. S. Barik, Immunophilins: for the love of proteins. Cell. Mol. Life Sci. 31, 1-12 (2006)
5. W.O. Bechstein, Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl. Int. 13, 313-326 (2000)
6. D. Boesch, C. Gaveriaux, B. Jachez, A. Pourtier-Manzanedo, P. Bollinger, F. Loor, In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51, 4226-4233 (1991)
7. F. Boscia, R. Gala, A. Pannaccione, A. Secondo, A. Scorziello, G. Di Renzo, L. Annunziato, NCX1 expression and functional activity increase in microglia invading the infarct core. Stroke 40, 3608-3617 (2009)
8. 2+ exchanger-3 (NCX3) impairs oligodendrocyte differentiation. Cell Death Differ. (2011). doi: 10.1038/cdd.2011.125 . Epub ahead of print
9. 2+ exchanger superfamily: phylogenetic analysis and structural implications. Mol. Biol. Evol. 21, 1692-1703 (2004)
10. E. Carafoli, Intracellular calcium homeostasis. Ann. Rev. Biochem. 56, 395-433 (1987)
11. H. Chen, Y. Kubo, T. Hoshi, S.H. Heinemann, Cyclosporin A selectively reduces the functional expression of Kir2.1 potassium channels in Xenopus oocytes. FEBS Lett. 422, 307-310 (1998)
12. 2+ exchanger. Am. J. Physiol. 290, C691-C701 (2006)
13. O. Cook, W. Low, H. Rahamimoff, Membrane topology of the rat brain sodium-calcium exchanger. Biochim. Biophys. Acta 1371, 40-52 (1998)
14. M. Crespo, M. Mir, M. Marin, S. Hurtado, C. Estadella, X. Guri, O. Rap, R. Moral, J.M. Puig, J. Lloveras, De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant. Proc. 41, 2115-2117 (2009)
15. 2+ exchanger expression by immunosuppressive drugs is isoform-speci fi c. Mol. Pharmacol. 73, 1254-1263 (2008)
16. 2+ exchanger NCX1. Biochemistry 49, 7634-7642 (2010)
17. 2+ exchanger in functional expression of the protein. M.sc. thesis, Submitted and approved by the Hebrew University -Hadassah Medical School, Jerusalem, 20111
18. M. Eskin-Schwartz, H. Rahamimoff, Expression of a mutant of the Na/Ca exchanger RBE-1 lacking 442 amino acids in the large cytoplasmic loop of the protein in HEK 293 cells. Neurosci. Lett. 54, S36 (1999)
19. M.R. First, Tacrolimus based immunosuppression. J. Nephrol. 17 (Suppl 8), S25-S31 (2004)
20. G. Fischer, B. Wittmann-Liebold, K. Lang, T. Kiefhaber, F.X. Schmid, Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337, 476-478 (1989)
21. A. Galat, Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr. Top. Med. Chem. 3, 1315-1347 (2003)
22. M.D. Galigniana, J.M. Harrell, H.M. O'Hagen, M. Ljungman, W.B. Pratt, Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J. Biol. Chem. 279, 22483-22489 (2004a)
23. M.D. Galigniana, Y. Morishima, P.A. Gallay, W.B. Pratt, Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complex. J. Biol. Chem. 279, 55754-55759 (2004b)
24. P.F. Halloran, Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351, 2715-2729 (2004)
25. S. Hariharan, C.P. Johnson, B.A. Bresnahan, S.E. Taranto, M.J. McIntosh, D. Stablein, Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342, 605-612 (2000)
26. S.A. Helekar, J. Patrick, Peptidyl prolyl cis-trans isomerase activity of cyclophilin A in functional homo-oligomeric receptor expression. Proc. Natl. Acad. Sci. U.S.A. 94, 5432-5437 (1997)
27. S.A. Helekar, D. Char, S. Neff, J. Patrick, Prolyl isomerase requirement for the expression of functional homooligomeric ligand-gated ion channels. Neuron 12, 179-189 (1994)
28. 2+ sensors. Mol. Cell 22, 15-25 (2006)
29. D.W. Holt, A. Johnston, B.D. Kahan, R.G. Morris, M. Oellerich, L.M. Shaw, New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin. Chem. 46, 872-874 (2000)
30. P. Hsiao, L. Sasongko, J.M. Link, D.A. Mankoff, M. Muzi, A.C. Collier, J.D. Unadkat, Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data. J. Pharmacol. Exp. Ther. 317, 704-710 (2006)
31. 2+ exchanger and the expressed NCX1 isoform to reactive oxygen species. Biochim. Biophys. Acta 1374, 34-46 (1998)
32. M.T. Ivery, Immunophilins: switched on protein binding domains? Med. Res. Rev. 20, 452-484 (2000)
33. 2+ exchange inhibitor that preferentially inhibits NCX3, ef fi ciently protects against hypoxia/reoxygenationinduced SH-SY5Y neuronal cell damage. Mol. Pharmacol. 70, 2075-2083 (2006)
34. 2+ exchanger. FEBS Lett. 446, 264-268 (1999a)
35. 2+ exchangers NCX1 and NCX3 reveals structural domains important for differential sensitivity to external Ni 2+ or Li + . J. Biol. Chem. 274, 23094-23102 (1999b)
36. 2+ exchanger RBE-1 (NCX1.4) impairs surface expression of the protein. J. Biol. Chem. 274, 24873-24880 (1999)
37. 2+ exchanger NCX1 is inhibited by the immunosuppressive agent cyclosporin A and the nonimmunosuppressive agent PSC833. J. Biol. Chem. 277, 2505-2510 (2002)
38. C.B. Klee, H. Ren, X. Wang, Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J. Biol. Chem. 273, 13367-13370 (1998)
39. S. Kochi, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, Y. Sawada, Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. Eur. J. Pharmacol. 372, 287-295 (1999)
40. R.R. Kopito, ER quality control: the cytoplasmic connection. Cell 88, 427-430 (1997)
41. B.K. Kramer, C. Boger, B. Kruger, J. Marienhagen, M. Pietrzyk, A. Obed, L. Paczek, M. Mack, B. Banas, Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplant. Proc. 37, 1868-1870 (2005)
42. B.K. Kramer, B. Charpentier, L. Backman, H.T. Silva Jr., G. Mondragon-Ramirez, E. Cassuto-Viguier, G. Mourad, R. Sola, P. Rigotti, J.O. Mirete, Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: A randomized phase III study. Am. J. Transplant. 10, 2632-2643 (2010)
43. K. Lang, F.X. Schmid, G. Fischer, Catalysis of protein folding by prolyl isomerase. Nature 329, 268-270 (1987)
44. M. Lemaire, A. Bruelisauer, P. Guntz, H. Sato, Dosedependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother. Pharmacol. 38, 481-486 (1996)
45. 2+ exchanger. J. Biol. Chem. 269, 22847-22852 (1994)
46. G.A. Levy, Neoral use in the liver transplant recipient. Transplant. Proc. 32 (3A Suppl), 2S-9S (2000)
47. J. Liu, M.W. Albers, T.J. Wandless, S. Luan, D.G. Alberg, P.J. Belshaw, P. Cohen, C. MacKintosh, C.B. Klee, S.L. Schreiber, Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 31, 3896-3901 (1992)
48. 2+ exchanger. Proc. Natl. Acad. Sci. U.S.A. 90, 3870-3874 (1993)
49. H.U. Meier-Kriesche, B.J. Steffen, A.H. Chu, J.J. Loveland, R.D. Gordon, J.A. Morris, B. Kaplan, Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am. J. Transplant. 4, 2058-2066 (2004)
50. H.U. Meier-Kriesche, A.H. Chu, K.M. David, K. Chi-Burris, B.J. Steffen, Switching immunosuppression medications after renal transplantation-a common practice. Nephrol. Dial. Transplant. 21, 2256-2262 (2006)
51. D, Mok, R.K. Allan, A. Carrello, K. Wangoo, M.D. Walkinshaw, T. Ratajczak, The chaperone function of cyclophilin 40 maps to a cleft between the prolyl isomerase and tetratricopeptide repeat domains. FEBS Lett. 580, 2761-2768 (2006)
52. 2+ exchanger. Science 250, 562-565 (1990)
53. 2+ exchanger, NCX3. J. Biol. Chem. 271, 24914-24921 (1996)
54. 2+ exchanger. J. Biol. Chem. 274, 910-917 (1999)
55. 2+ binding motif. J. Biol. Chem. 281, 21577-25181 (2006)
56. M. Oellerich, V.W. Armstrong, B. Kahan, L. Shaw, D.W. Holt, R. Yatscoff, A. Lindholm, P. Halloran, K. Gallicano, K. Wonigeit et al., Lake louise consensus conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther. Drug Monit. 17, 642-654 (1995)
57. 2+ exchanger from Drosophila Melanogaster. J. Gen. Physiol. 111, 691-702 (1998)
58. C. On, C.R. Marshall, S.F. Perry, H.D. Le, V. Yurkov, A. Omelchenko, M. Hnatowich, L.V. Hryshko, G.F. Tibbits, Characterization of zebra fish (Danio rerio) NCX4: A novel NCX with distinct electrophysiological properties. Am. J. Physiol. 296, C173-C181 (2009)
59. 2+ exchanger NCX1. Am. J. Physiol. 279, C393-C402 (2000)
60. 2+ exchanger contributes to neuroprotection elicited by ischemic postconditioning. J. Cereb. Blood Flow Metab. 31, 362-370 (2011)
61. F. Pirkl, E. Fischer, S. Modrow, J. Buchner, Localization of the chaperone domain of FKBP52. J. Biol. Chem. 276, 37034-37041 (2001)
62. K. Pong, M.M. Zaleska, Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr. Drug Targets CNS Neurol. Disord. 2, 349-356 (2003)
63. E.R. Price, M. Jin, D. Lim, S. Pati, C.T. Walsh, F.D. McKeon, Cyclophilin B Trafficking through the secretory pathway is altered by binding of cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 91, 3931-3935 (1994)
64. C.G. Proud, Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem. J. 403, 217-234 (2007)
65. B.D. Quednau, D.A. Nicoll, K.D. Philipson, The sodium/calcium exchanger family-SLC8. Pflugers Arch. 447, 543-548 (2004) Epub 2003 May 77
66. 2+ exchanger expression. Ann. N. Y. Acad. Sci. 1099, 204-214 (2007)
67. S.L. Schreiber, Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251, 283-287 (1991)
68. E.M. Schwarz, S. Benzer, Calx, a Na-Ca exchanger gene of Drosophila Melanogaster. Proc. Natl. Acad. Sci. U.S.A. 94, 10249-10254 (1997)
69. A. Shirai, M. Naito, T. Tatsuta, J. Dong, K. Hanaoka, K. Mikami, T. Oh-hara, T. Tsuruo, Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. Biophys. Acta 1222, 400-404 (1994)
70. H.L. Tai, Technology evaluation: Valspodar, Novartis AG. Curr. Opin. Mol. Ther. 2, 459-467 (2000)
71. T.T. Tran, W. Dai, H.K. Sarkar, Cyclosporin A inhibits creatine uptake by altering surface expression of the creatine transporter. J. Biol. Chem. 275, 35708-35714 (2000)
72. P. Trunecka, O. Boillot, D. Seehofer, A.D. Pinna, L. Fischer, B.G. Ericzon, R.I. Troisi, U. Baccarani, J. Ortizde Urbina, W. Wall, Once-daily prolongedrelease tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am. J. Transplant. 10, 2313-2323 (2010)
73. C.K. Tsang, H. Qi, L.F. Liu, X.F. Zheng, Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12, 112-124 (2007)
74. A. von Harpe, H. Petersen, Y. Li, T. Kissel, Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release 69, 309-322 (2000)
75. X, Wang, C.G. Proud, The mTOR pathway in the control of protein synthesis. Physiology (Bethesda, Md.) 21, 362-369 (2006)
76. L.D. Zydowsky, F.A. Etzkorn, H.Y. Chang, S.B. Ferguson, L.A. Stolz, S.I. Ho, C.T. Walsh, Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci. 1, 1092-1099 (1992)